A meta-analysis of 18 randomized controlled trials looked at how to best treat Kawasaki disease in children. Researchers compared a combination of dipyridamole, immunoglobulin, and aspirin against the standard treatment of just immunoglobulin and aspirin. The study included data from 1,594 children.
The results showed that adding dipyridamole led to a significantly higher total effective rate for patients. Children receiving the combined treatment also saw faster improvements in clinical symptoms. Additionally, markers like C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fibrinogen levels were lower in the group receiving dipyridamole. The study also found lower platelet counts and fewer coronary artery lesions in that group.
In terms of safety, there was no significant difference in adverse reactions between the two treatment groups. While these results suggest that adding dipyridamole may be more effective for managing Kawasaki disease symptoms and markers, it is important to remember this is a summary of several studies. Patients and families should discuss these findings with their doctors to determine the best treatment plan.
